Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.63 |
| ▸ | FLT1 | P17948 | 4/20 | 0.63 |
| ▸ | FLT4 | P35916 | 4/20 | 0.63 |
| ▸ | RET | P07949 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | KIT | P10721 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 3/20 | 0.46 |
| ▸ | MET | P08581 | 3/20 | 0.46 |
| ▸ | TEK | Q02763 | 3/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL272878 | 0.86 | KDR (0.55) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL10260513 | 0.86 | KDR (0.78) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2710044 | 0.85 | KDR (0.52) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2706640 | 0.85 | KDR (0.53) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2709724 | 0.84 | KDR (0.49) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL987727 | 0.83 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2708528 | 0.83 | KDR (0.64) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2708541 | 0.82 | KDR (0.49) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2706582 | 0.82 | KDR (0.53) | KDRFLT1FLT4RETPDGFRB | |
| SCHEMBL2434197 | 0.82 | KDR (0.70) | KDRFLT1FLT4BRAFMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632458-B1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| EP-2632458-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | Novartis AG (CH) | 2013-09-04 | — | — | EP | claimed |
| US-20130197016-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-08-01 | — | — | US | claimed |
| US-8217045-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | claimed |
| WO-2012055884-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2012-05-03 | — | — | WO | claimed |
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG | 2011-12-08 | — | — | US | claimed |
| US-20100113467-A1 | Organic Compounds | NOVARTIS AG | 2010-05-06 | — | — | US | claimed |
| EP-2146964-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | Novartis Ag (CH) | 2010-01-27 | — | — | EP | claimed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | claimed |
| EP-2632458-B1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | disclosed |
| EP-2632458-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | Novartis AG (CH) | 2013-09-04 | — | — | EP | disclosed |
| US-20130197016-A1 | DOSING REGIMES FOR THE TREATMENT OF OCULAR VASCULAR DISEASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-08-01 | — | — | US | disclosed |
| US-8217045-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-07-10 | — | — | US | disclosed |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | NOVARTIS AG (CH) | 2012-07-05 | — | — | US | disclosed |
| WO-2008125691-A2 | ETHERS OF NAPHTALENE CARBOXYLIC ACID AMIDES AS CANCER CURE | NOVARTIS AG (CH) | 2008-10-23 | — | — | WO | disclosed |
| EP-1945217-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | Novartis AG (CH) | 2008-07-23 | — | — | EP | disclosed |
| EP-1794149-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007031265-A2 | COMBINATIONS COMPRISING A VEGF RECEPTOR INHIBITOR AND A PENETRATION ENHANCER | NOVARTIS AG (CH) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006059234-A2 | BICYCLIC AMIDES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301157-A1 | BICYCLIC AMIDES AS KINASE INHIBITORS | MAP3K20, MAP3K1, MAP3K19 | KDR 826/4885FLT1 638/4885FLT4 944/4885 |
| US-20100113467-A1 | Organic Compounds | SLCO2A1, SLCO1B1, SLCO2B1 | KDR 4081/4885FLT1 3221/4885FLT4 3842/4885 |
| US-20120172386-A1 | Combinations Comprising a VEGF Receptor Inhibitor | KDR, FLT4, FLT1 | KDR 1/4885FLT1 3/4885FLT4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.